- Home
- ESAB vs LEGN Comparison
ESAB vs LEGN Comparison
Compare ESAB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- LEGN
- Stock Information
- Founded
- ESAB 1904
- LEGN 2014
- Country
- ESAB United States
- LEGN United States
- Employees
- ESAB N/A
- LEGN N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- LEGN Health Care
- Exchange
- ESAB Nasdaq
- LEGN Nasdaq
- Market Cap
- ESAB 6.9B
- LEGN 7.0B
- IPO Year
- ESAB N/A
- LEGN 2020
- Fundamental
- Price
- ESAB $130.31
- LEGN $27.78
- Analyst Decision
- ESAB Buy
- LEGN Strong Buy
- Analyst Count
- ESAB 8
- LEGN 13
- Target Price
- ESAB $136.13
- LEGN $75.67
- AVG Volume (30 Days)
- ESAB 278.9K
- LEGN 1.5M
- Earning Date
- ESAB 05-01-2025
- LEGN 05-13-2025
- Dividend Yield
- ESAB 0.31%
- LEGN N/A
- EPS Growth
- ESAB 16.34
- LEGN N/A
- EPS
- ESAB 4.43
- LEGN N/A
- Revenue
- ESAB $2,729,197,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ESAB N/A
- LEGN $65.96
- Revenue Next Year
- ESAB $4.79
- LEGN $52.55
- P/E Ratio
- ESAB $29.37
- LEGN N/A
- Revenue Growth
- ESAB N/A
- LEGN 112.46
- 52 Week Low
- ESAB $88.54
- LEGN $29.27
- 52 Week High
- ESAB $135.97
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ESAB 65.90
- LEGN 29.61
- Support Level
- ESAB $126.89
- LEGN $30.25
- Resistance Level
- ESAB $132.55
- LEGN $33.30
- Average True Range (ATR)
- ESAB 3.58
- LEGN 1.78
- MACD
- ESAB 0.91
- LEGN -0.57
- Stochastic Oscillator
- ESAB 87.69
- LEGN 5.19
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.